Free Trial
NASDAQ:CDTX

Cidara Therapeutics (CDTX) Stock Price, News & Analysis

Cidara Therapeutics logo
$62.46 -0.44 (-0.70%)
Closing price 04:00 PM Eastern
Extended Trading
$62.50 +0.04 (+0.06%)
As of 04:36 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Cidara Therapeutics Stock (NASDAQ:CDTX)

Key Stats

Today's Range
$62.14
$63.48
50-Day Range
$21.02
$64.85
52-Week Range
$10.14
$66.94
Volume
238,321 shs
Average Volume
369,357 shs
Market Capitalization
$1.26 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$57.29
Consensus Rating
Buy

Company Overview

Cidara Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
58th Percentile Overall Score

CDTX MarketRank™: 

Cidara Therapeutics scored higher than 58% of companies evaluated by MarketBeat, and ranked 422nd out of 919 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Cidara Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.11, and is based on 8 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Cidara Therapeutics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Cidara Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Cidara Therapeutics are expected to decrease in the coming year, from ($8.74) to ($14.39) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Cidara Therapeutics is -2.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Cidara Therapeutics is -2.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Cidara Therapeutics has a P/B Ratio of 4.20. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Cidara Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    12.98% of the float of Cidara Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Cidara Therapeutics has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Cidara Therapeutics has recently increased by 40.99%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Cidara Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Cidara Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    12.98% of the float of Cidara Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Cidara Therapeutics has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Cidara Therapeutics has recently increased by 40.99%, indicating that investor sentiment is decreasing significantly.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Cidara Therapeutics this week, compared to 3 articles on an average week.
  • Search Interest

    12 people have searched for CDTX on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.
  • MarketBeat Follows

    Only 2 people have added Cidara Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -60% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Cidara Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $99,999,988.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    Only 7.64% of the stock of Cidara Therapeutics is held by insiders.

  • Percentage Held by Institutions

    Only 35.82% of the stock of Cidara Therapeutics is held by institutions.

  • Read more about Cidara Therapeutics' insider trading history.
Receive CDTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cidara Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CDTX Stock News Headlines

Market Panic: Trump Just Dropped a Bomb on Your Stocks
tock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tariffs just lit the fuse. Millions of investors are blindsided as stocks plunge… but this is only Phase 1. If you're still holding the wrong assets, you could lose 30% or more in the coming weeks.
Cidara Therapeutics Inc (CDTX) - Investing.com UK
See More Headlines

CDTX Stock Analysis - Frequently Asked Questions

Cidara Therapeutics' stock was trading at $26.88 at the start of the year. Since then, CDTX shares have increased by 133.3% and is now trading at $62.7160.

Cidara Therapeutics, Inc. (NASDAQ:CDTX) announced its quarterly earnings data on Thursday, May, 8th. The biotechnology company reported ($1.66) EPS for the quarter, beating analysts' consensus estimates of ($5.45) by $3.79.
Read the conference call transcript
.

Shares of Cidara Therapeutics reverse split before market open on Wednesday, April 24th 2024.The 1-20 reverse split was announced on Wednesday, April 24th 2024. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, April 24th 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Cidara Therapeutics (CDTX) raised $60 million in an initial public offering on Wednesday, April 15th 2015. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Jefferies and Leerink Partners served as the underwriters for the IPO and Wedbush PacGrow Life Sciences, Needham and BTIG were co-managers.

Top institutional investors of Cidara Therapeutics include Aberdeen Group plc (1.29%), Jennison Associates LLC (0.24%), West Michigan Advisors LLC (0.08%) and AlphaQuest LLC (0.02%). Insiders that own company stock include Ra Capital Management, LP, Jeffrey Stein, Taylor Sandison, Leslie Tari, Shane Ward, Preetam Shah and Paul Daruwala.
View institutional ownership trends
.

Shares of CDTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Cidara Therapeutics investors own include Meta Platforms (META), VBI Vaccines (VBIV), SCYNEXIS (SCYX), NVIDIA (NVDA), CRISPR Therapeutics (CRSP), Sorrento Therapeutics (SRNE) and Inovio Pharmaceuticals (INO).

Company Calendar

Last Earnings
5/08/2025
Today
8/04/2025
Next Earnings (Estimated)
8/07/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:CDTX
CIK
1610618
Fax
N/A
Employees
90
Year Founded
N/A

Price Target and Rating

High Price Target
$75.00
Low Price Target
$45.00
Potential Upside/Downside
-8.6%
Consensus Rating
Buy
Rating Score (0-4)
3.11
Research Coverage
9 Analysts

Profitability

EPS (Trailing Twelve Months)
($29.47)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$169.83 million
Net Margins
N/A
Pretax Margin
-61,454.97%
Return on Equity
-73.04%
Return on Assets
-54.28%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
3.87
Quick Ratio
3.87

Sales & Book Value

Annual Sales
$1.27 million
Price / Sales
995.30
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$14.92 per share
Price / Book
4.20

Miscellaneous

Outstanding Shares
20,160,000
Free Float
18,623,000
Market Cap
$1.26 billion
Optionable
No Data
Beta
1.18

Social Links

Analysts Agree—These Gold Picks Outshine the Rest Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (NASDAQ:CDTX) was last updated on 8/4/2025 by MarketBeat.com Staff
From Our Partners